Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
69.70    -0.40 (-0.57%)
Bid:
69.50
Ask:
69.70
Spread: 0.20 (0.288%)
Market Cap: £667.09m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Directorate Change

24 Mar 2023 07:00

RNS Number : 0822U
Dr. Martens PLC
24 March 2023
 

Dr. Martens plc

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

 

Dr. Martens plc ('the Company') today announces that, following a comprehensive search and selection process, Andrew Harrison will join the Board as an Independent Non-Executive Director with effect from 1 May 2023.

 

Andrew is a managing partner at consumer brand investment firm Freston Ventures and Senior Independent Director at Ocado Group plc, proprietor of the Ocado Smart Platform and joint owner of online grocer Ocado Retail Limited, where he is also chair of the Remuneration Committee and designated Non-Executive Director for engagement with the workforce. He built his executive career over more than two decades at Carphone Warehouse, where he served as Chief Executive and Chair. As a member of the early founding team, he drove the growth and international expansion of Carphone Warehouse from a small, privately owned retailer to established market leader and FTSE constituent, subsequently leading the merger of the business with Dixons in 2014, where he was Deputy Chief Executive.

 

Paul Mason, Chairman, said:

 

"I am delighted to welcome Andrew to the Dr. Martens Board. He brings a wealth of expertise of consumer facing and technology focused businesses and a highly entrepreneurial mindset. His significant prior experience as both a Chief Executive and Non-Executive Director of large, listed companies will bolster the Board and will be invaluable to the business as we embark on the next chapter of the Dr. Martens story."

 

On joining the Board, Andrew will also become a member of the Audit, Remuneration and Nomination Committees.

 

The Company confirms that there is no further information required to be disclosed pursuant to paragraph 9.6.13 of the UK Listing Rules.

 

 

Enquiries

 

Investors and analysts

Mark Blythman, Interim Director of Investor Relations +44 7570 871207

mark.blythman@drmartens.com

Media

Gill Hammond, Director of Communications +44 7384 214248

 

H/Advisors Maitland

Rhys Jones +44 7881 996460

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. 

 

The Company listed successfully on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEAFUDEDSEED
Date   Source Headline
30th Mar 20227:00 amRNSBlock Listing Application
22nd Mar 20227:43 amRNSDirector Declaration
31st Jan 20224:23 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSTrading Statement
11th Jan 20224:11 pmRNSDirector/PDMR Shareholding
10th Jan 20225:15 pmRNSHolding(s) in Company
6th Jan 20225:30 pmRNSDr Martens
6th Jan 20227:00 amRNSResult of Secondary Placing in Dr. Martens
5th Jan 20225:12 pmRNSProposed Secondary Placing in Dr. Martens plc
13th Dec 20211:33 pmRNSChange of Auditor
9th Dec 20217:00 amRNSHalf-year Report
1st Nov 202112:53 pmRNSTotal Voting Rights
30th Sep 20218:45 amRNSBlock Listing Application
15th Sep 20217:00 amRNSDirector/PDMR Shareholding
29th Jul 20211:06 pmRNSResult of AGM
29th Jul 20217:00 amRNSTrading Statement
12th Jul 202110:00 amRNSPrior year quarterly revenue figures
1st Jul 20219:00 amRNSAnnual Financial Report
25th Jun 202112:46 pmRNSHolding(s) in Company
23rd Jun 20216:19 pmRNSHolding(s) in Company
21st Jun 202110:39 amRNSDirector/PDMR Shareholding
18th Jun 20213:16 pmRNSHolding(s) in Company
17th Jun 20217:00 amRNSFinal Results
16th Jun 20215:40 pmRNSHolding(s) in Company
13th Apr 20217:00 amRNSAppointment of Joint Corporate Brokers
10th Feb 20219:00 amRNSDirector/PDMR Shareholding
9th Feb 20211:41 pmRNSHolding(s) in Company
5th Feb 202112:52 pmRNSHolding(s) in Company
5th Feb 20219:20 amRNSExercise of Over-allotment Option
4th Feb 20215:20 pmRNSHolding(s) in Company
3rd Feb 20218:00 amRNSTotal Voting Rights
3rd Feb 20218:00 amRNSAdmission to Trading on the London Stock Exchange
1st Feb 20214:53 pmRNSDirector/PDMR Shareholding
29th Jan 202111:18 amRNSStabilisation Notice
29th Jan 202110:48 amRNSApproval and Publication of Prospectus
29th Jan 20217:00 amRNSAnnouncement of Offer Price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.